EPO and myeloid sarcoma: In conclusion, we provide evidence that VCE-004.8 is a promising small molecule to modulate relevant MS targets, being endowed with PPARγ and CB2-mediated neuroinflammatory activity, and may enhance remyelination by inhibiting PHD activity and inducing neuroprotective factors such as VEGF and EPO.